Krebs Biochemicals and Industries quarterly results

·Pharma & HealthChart ›
Q2 FY27 · Jul–Sep 2026
₹ croreQ2 FY27Q2 FY26Change
Revenue5.84.2+38.9%
EBITDA−1.9−2.8—
EBITDA margin−33.3%−67.0%+33.7 pts
Profit before tax−5.4−6.1—
Net profit−5.4−6.1—
EPS−₹2.50−₹2.85—

Every quarter

₹ crore except per share
Tap a line for its trendQ2 FY27Sep 2026Q1 FY27Jun 2026Q4 FY26Mar 2026Q3 FY26Dec 2025Q2 FY26Sep 2025Q1 FY26Jun 2025Q4 FY25Mar 2025Q3 FY25Dec 2024Q2 FY25Sep 2024Q1 FY25Jun 2024Q4 FY24Mar 2024Q3 FY24Dec 2023Earlier quartersAlpha Plus
5.87.06.87.34.25.56.111.512.912.912.013.0
Earlier quartersEvery year the company has filed comes with Alpha Plus.
0.00.22.00.00.00.00.30.30.10.00.20.0
5.87.18.87.34.25.56.411.712.912.912.213.0
Expenses
0.3−0.00.00.00.00.0−0.11.21.00.41.81.0
0.00.50.00.00.00.00.00.00.00.00.10.0
1.0−0.10.10.00.00.20.70.11.40.81.00.2
2.82.82.32.72.72.83.54.54.44.23.94.4
1.91.91.91.81.71.71.61.61.41.31.31.2
1.61.61.61.61.61.61.61.71.71.71.71.7
3.63.05.34.34.34.57.510.48.89.68.39.3
11.29.611.210.410.310.814.719.518.718.118.018.0
−1.90.8−0.90.3−2.8−2.1−5.4−4.7−2.7−2.2−3.1−2.1
−3.5−0.8−2.4−1.3−4.4−3.7−7.0−6.4−4.4−3.9−4.8−3.8
Profit
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
0.00.00.00.00.00.00.00.00.00.00.00.0
0.00.00.00.00.00.00.00.00.00.00.00.0
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
0.00.00.40.00.00.0−0.10.00.00.0−0.00.0
−5.4−2.5−1.9−3.1−6.1−5.3−8.4−7.7−5.8−5.2−5.9−5.0
Per share
−₹2.50−₹1.15−₹1.09−₹1.45−₹2.85−₹2.47−₹3.83−₹3.59−₹2.67−₹2.40−₹2.72−₹2.31
−₹2.50−₹1.15−₹1.09−₹1.45−₹2.85−₹2.47−₹3.83−₹3.59−₹2.67−₹2.40−₹2.72−₹2.31
Other comprehensive income — detail
0.0—0.4———−0.1—————
——0.4———−0.1———−0.0—
Per share — as-filed variants
−₹2.50−₹1.15−₹1.09−₹1.45−₹2.85−₹2.47−₹3.83−₹3.59−₹2.67−₹2.40−₹2.72−₹2.31
−₹2.50−₹1.15−₹1.09−₹1.45−₹2.85−₹2.47−₹3.83−₹3.59−₹2.67−₹2.40−₹2.72−₹2.31
Regulatory disclosures — filed alongside, not part of the P&L
18.6—21.3—22.1—30.5—————
Derived — gross profit (revenue − materials − purchases − Δ inventories)
4.56.66.77.34.25.2—10.210.411.69.111.7
77.6%94.1%98.6%100.0%100.0%94.7%—88.6%81.2%90.2%75.9%90.2%
Adjusted (ex-exceptional items) — derived
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
−5.4−2.5−2.3−3.1−6.1−5.3−8.3−7.7−5.8−5.2−5.8−5.0
−₹2.50−₹1.15−₹1.09−₹1.45−₹2.85−₹2.47−₹3.83−₹3.59−₹2.67−₹2.40−₹2.72−₹2.31
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KREBSBIO₹59.15

Krebs Biochemicals and Industries Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersALPABALPHARMAVINEETLABNATCAPSUQBIOFILCHEMNECLIFEMANGALAMAAREYDRUGSMcap ₹128 Cr
View
In ₹ Crore except Per Share
3 Months Ending
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Revenue from Operations13.012.012.912.911.56.15.54.27.36.87.05.8
Other Income0.00.20.00.10.30.30.00.00.02.00.20.0
Total Income13.012.212.912.911.76.45.54.27.38.87.15.8
Expenses
+ Cost of Materials Consumed1.01.80.41.01.2-0.10.00.00.00.0-0.00.3
+ Purchases of Stock-in-Trade0.00.10.00.00.00.00.00.00.00.00.50.0
+ Changes in Inventories0.21.00.81.40.10.70.20.00.00.1-0.11.0
+ Employee Benefit Expense4.43.94.24.44.53.52.82.72.72.32.82.8
+ Finance Costs1.21.31.31.41.61.61.71.71.81.91.91.9
+ Depreciation & Amortisation1.71.71.71.71.71.61.61.61.61.61.61.6
+ Other Expenses9.38.39.68.810.47.54.54.34.35.33.03.6
Total Expenses18.018.018.118.719.514.710.810.310.411.29.611.2
EBITDA-2.1-3.1-2.2-2.7-4.7-5.4-2.1-2.80.3-0.90.8-1.9
EBIT-3.8-4.8-3.9-4.4-6.4-7.0-3.7-4.4-1.3-2.4-0.8-3.5
Profit
PBT before Exceptional Items-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
Pretax Income-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
+ Current Tax0.00.00.00.00.00.00.00.00.00.00.00.0
Tax Expense0.00.00.00.00.00.00.00.00.00.00.00.0
Net Income-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
+ Net Income — Continuing Ops-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
+ Other Comprehensive Income0.0-0.00.00.00.0-0.10.00.00.00.40.00.0
Total Comprehensive Income-5.0-5.9-5.2-5.8-7.7-8.4-5.3-6.1-3.1-1.9-2.5-5.4
Per Share
Basic EPS-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Diluted EPS-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Other Comprehensive Income — detail
+ Other Comprehensive Income—————-0.1———0.4—0.0
+ Items NOT to be Reclassified to P&L—-0.0———-0.1———0.4——
Per Share — as-filed variants
Basic EPS — Continuing Operations-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Diluted EPS — Continuing Operations-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period—————30.5—22.1—21.3—18.6
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit11.79.111.610.410.2—5.24.27.36.76.64.5
Gross Margin %90.1675.8690.2481.1788.58—94.7299.9699.9898.5694.1177.64
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
Net Income Adj (tax-effected)-5.0-5.8-5.2-5.8-7.7-8.3-5.3-6.1-3.1-2.3-2.5-5.4
EPS Adj-2.31-2.72-2.40-2.67-3.59-3.83-2.47-2.85-1.45-1.09-1.15-2.50
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital21.621.621.621.621.621.621.621.621.621.621.621.6
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q2 FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Krebs Biochemicals and Industries Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 1:10 pm IST

Krebs Biochemicals and Industries (NSE: KREBSBIO) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 1:10 pm IST. Consolidated net loss was ₹5.4 crore, narrower than the loss of ₹6.1 crore in Q2 FY26 and wider than the loss of ₹2.5 crore in Q1 FY27. Revenue from operations was ₹5.8 crore, up 38.9% year on year and down 17.1% from the previous quarter.

Q2 FY26 results (a year earlier)
4 November 2025
Q3 FY27 results due by
14 February 2027

Q2 FY27 at a glance · consolidated

Net loss
−₹5.4 Crloss ₹6.1 Cr in Q2 FY26loss ₹2.5 Cr in Q1 FY27
Revenue from operations
₹5.8 Cr+38.9% vs Q2 FY26−17.1% vs Q1 FY27
Operating margin (EBIT)
−61.0%−50.1 pts vs Q1 FY27EBIT −₹3.5 Cr
EBITDA
−₹1.9 Cr₹83 lakh in Q1 FY27margin −33.3%
Earnings per share (basic)
−₹2.50
Net profit margin
−93.2%+54.2 pts vs Q2 FY26−57.7 pts vs Q1 FY27

Questions

What was Krebs Biochemicals and Industries' net profit in Q2 FY27?

Consolidated net loss was ₹5.4 crore, narrower than the loss of ₹6.1 crore in Q2 FY26 and wider than the loss of ₹2.5 crore in Q1 FY27.

What was Krebs Biochemicals and Industries' revenue in Q2 FY27?

Revenue from operations was ₹5.8 crore, up 38.9% year on year and down 17.1% from the previous quarter.

How were Krebs Biochemicals and Industries' Q2 FY27 results?

A net loss of ₹5.4 crore, narrower than the loss of ₹6.1 crore in Q2 FY26. Revenue was up 38.9% at ₹5.8 crore.

What was Krebs Biochemicals and Industries' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was −₹3.5 crore, a margin of −61.0%, against −10.9% in Q1 FY27. EBITDA was −₹1.9 crore, −33.3% of revenue.

What was Krebs Biochemicals and Industries' net profit in the first half of FY27?

Consolidated net loss for the first half of FY27 (April–September 2026) was ₹7.9 crore, narrower than the loss of ₹11.5 crore in the same months a year earlier. Revenue from operations was ₹12.8 crore, up 32.4%.

What is Krebs Biochemicals and Industries' net profit margin?

Krebs Biochemicals and Industries' net profit margin was −93.2% in Q2 FY27 (net profit as a share of revenue from operations), against −147.4% in Q2 FY26 (up 54.2 percentage points). For FY26 as a whole it was −71.4%.

What was Krebs Biochemicals and Industries' EPS in Q2 FY27?

Basic earnings per share were −₹2.50, against −₹2.85 in Q2 FY26.

What was Krebs Biochemicals and Industries' net profit in FY26?

Consolidated net profit was a loss of ₹16.9 crore in FY26 (April 2025–March 2026), narrower than the loss of ₹26.9 crore in FY25. It was a loss of ₹19.7 crore in FY24 and a loss of ₹24.7 crore in FY23.

When did Krebs Biochemicals and Industries announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 1:10 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 4 November 2025.

How has Krebs Biochemicals and Industries' profit changed over the last four quarters?

Net profit by quarter: a loss of ₹3.1 crore in Q3 FY26, a loss of ₹2.3 crore in Q4 FY26, a loss of ₹2.5 crore in Q1 FY27 and a loss of ₹5.4 crore in Q2 FY27. That is a combined loss of ₹13.3 crore over the four quarters. Revenue from operations: ₹7.3 crore, ₹6.8 crore, ₹7 crore and ₹5.8 crore.

What was Krebs Biochemicals and Industries' revenue in FY26?

Revenue from operations was ₹23.7 crore in FY26 (April 2025–March 2026), down 45.2% from ₹43.3 crore in FY25. It was ₹50.4 crore in FY24 and ₹52.1 crore in FY23: down 54.5% over three years, an average fall of 23.1% a year.

When will Krebs Biochemicals and Industries announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Krebs Biochemicals and Industries figures come from?

From Krebs Biochemicals and Industries' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.